Mild Cognitive Impairment – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Mild Cognitive Impairment – Pipeline Review, H1 2018’, provides an overview of the Mild Cognitive Impairment pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment

– The report reviews pipeline therapeutics for Mild Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Mild Cognitive Impairment therapeutics and enlists all their major and minor projects

– The report assesses Mild Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

AgeneBio Inc

Avraham Pharmaceuticals Ltd

Biogen Inc

CereSpir Inc

Eisai Co Ltd

Eli Lilly and Co

Genzyme Corp

IntelGenx Corp

Krenitsky Pharmaceuticals Inc

Neuron Biopharma SA

Octapharma AG

Pfizer Inc

Sage Therapeutics Inc

SBI Pharmaceuticals Co Ltd

Suven Life Sciences Ltd

Takeda Pharmaceutical Co Ltd

Therapix Biosciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mild Cognitive Impairment Overview

Mild Cognitive Impairment Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Mild Cognitive Impairment Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mild Cognitive Impairment Companies Involved in Therapeutics Development

AbbVie Inc

AgeneBio Inc

Avraham Pharmaceuticals Ltd

Biogen Inc

CereSpir Inc

Eisai Co Ltd

Eli Lilly and Co

Genzyme Corp

IntelGenx Corp

Krenitsky Pharmaceuticals Inc

Neuron Biopharma SA

Octapharma AG

Pfizer Inc

Sage Therapeutics Inc

SBI Pharmaceuticals Co Ltd

Suven Life Sciences Ltd

Takeda Pharmaceutical Co Ltd

Therapix Biosciences Ltd

Mild Cognitive Impairment Drug Profiles

ABBV-8E12 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aminolevulinic acid hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAN-2401 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bosutinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brexanolone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSP-1103 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DAOI-B Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elenbecestat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gosuranemab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-544 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ladostigil tartrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levetiracetam ER Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levofacetoperane Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3002813 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3303560 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

montelukast sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MW-151 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neflamapimod Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPS-0158 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPS-0163 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NST-0037 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NST-0076 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NST-0078 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-38 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sargramostim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GABRA5 Receptor for CNS Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit EIF2AK2 for Mild Cognitive Impairment Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-501 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-507 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-512 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-071 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THX-130 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mild Cognitive Impairment Dormant Projects

Mild Cognitive Impairment Discontinued Products

Mild Cognitive Impairment Product Development Milestones

Featured News & Press Releases

Sep 27, 2017: Therapixs First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study

Oct 31, 2016: Therapix Biosciences Successfully Completed the Development of a Formulation for a Tablet for Sublingual Administration of THC for Pharmaceutical Use

Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain

Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast

Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment

Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI

Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON

May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment

Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Mild Cognitive Impairment, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Mild Cognitive Impairment Pipeline by AbbVie Inc, H1 2018

Mild Cognitive Impairment Pipeline by AgeneBio Inc, H1 2018

Mild Cognitive Impairment Pipeline by Avraham Pharmaceuticals Ltd, H1 2018

Mild Cognitive Impairment Pipeline by Biogen Inc, H1 2018

Mild Cognitive Impairment Pipeline by CereSpir Inc, H1 2018

Mild Cognitive Impairment Pipeline by Eisai Co Ltd, H1 2018

Mild Cognitive Impairment Pipeline by Eli Lilly and Co, H1 2018

Mild Cognitive Impairment Pipeline by Genzyme Corp, H1 2018

Mild Cognitive Impairment Pipeline by IntelGenx Corp, H1 2018

Mild Cognitive Impairment Pipeline by Krenitsky Pharmaceuticals Inc, H1 2018

Mild Cognitive Impairment Pipeline by Neuron Biopharma SA, H1 2018

Mild Cognitive Impairment Pipeline by Octapharma AG, H1 2018

Mild Cognitive Impairment Pipeline by Pfizer Inc, H1 2018

Mild Cognitive Impairment Pipeline by Sage Therapeutics Inc, H1 2018

Mild Cognitive Impairment Pipeline by SBI Pharmaceuticals Co Ltd, H1 2018

Mild Cognitive Impairment Pipeline by Suven Life Sciences Ltd, H1 2018

Mild Cognitive Impairment Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Mild Cognitive Impairment Pipeline by Therapix Biosciences Ltd, H1 2018

Mild Cognitive Impairment Dormant Projects, H1 2018

Mild Cognitive Impairment Dormant Projects, H1 2018 (Contd..1), H1 2018

Mild Cognitive Impairment Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Mild Cognitive Impairment, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports